IPO Databook: Jaguar Health (JAGX US) - Jul 2026

109 Views26 Jul 2026 10:10

SUMMARY

Jaguar Health develops novel plant-derived prescription drugs for human GI diseases and non-prescription GI products for animals. This prospectus registers shares for resale by a selling stockholder.
Jaguar Health received $16.0 million non-dilutive capital in January 2026 from Future Pak, with potential for $20 million in milestone payments. Crofelemer received Orphan Drug Designation for MVID.
The company holds global unencumbered rights for crofelemer, an FDA-approved drug. Future stock resales and issuances may cause market price decline.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream